aramchol

10/01/2021 - "NASH resolution without worsening fibrosis was achieved in 16.7% (13 out of 78) of Aramchol 600 mg versus 5% (2 out of 40) of the placebo arm (odds ratio (OR) = 4.74, 95% CI = 0.99 to 22.7) and fibrosis improvement by ≥1 stage without worsening NASH in 29.5% versus 17.5% (OR = 1.88, 95% CI = 0.7 to 5.0), respectively. "
06/01/2021 - "These findings illustrate novel mechanisms of Aramchol activity, including potential antifibrotic activity in patients with NASH and fibrosis. "
11/01/2017 - "Aramchol treatment improved steatohepatitis and fibrosis by 1) decreasing SCD1, and 2) increasing the flux through the transsulfuration pathway maintaining cellular redox homeostasis. "
11/01/2017 - "Aramchol administration reduced features of steatohepatitis and fibrosis in 0.1MCD fed mice. "
11/01/2017 - "Role of Aramchol in steatohepatitis and fibrosis in mice."

01/01/2023 - "To evaluate the efficacy of Aramchol in patients with NAFLD according to different randomized clinical trials. "
01/01/2023 - "We searched PubMed, SCOPUS, Web of Science, and Cochrane Library for relevant clinical trials assessing the use of Aramchol in patients with NAFLD. "
05/01/2022 - "Aramchol, a SCD1 inhibitor, significantly blocks adipogenesis (markedly TG decrease, p < 0.001).Our study broadens the understanding of the role of Ndufb9 in adipogenesis and provides a new target for the treatment of NAFLD."
10/01/2021 - "Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial."
01/01/2023 - "Aramchol was a safe and tolerable drug to be used in patients with NAFLD. "

08/01/2003 - "The present study was designed to study the effect of FABAC (arachidyl-amido-cholanoic acid) on diet-induced fatty liver in rats, hamsters, and mice. "
12/01/2014 - "The reduction in liver fat content occurred in a dose-dependent manner and was associated with a trend of metabolic improvements, indicating that Aramchol might be used for the treatment of fatty liver disease. "
11/01/2017 - "Aramchol treatment improved steatohepatitis and fibrosis by 1) decreasing SCD1, and 2) increasing the flux through the transsulfuration pathway maintaining cellular redox homeostasis. "
11/01/2017 - "Aramchol administration reduced features of steatohepatitis and fibrosis in 0.1MCD fed mice. "
11/01/2017 - "Role of Aramchol in steatohepatitis and fibrosis in mice."

11/01/2019 - "The aramchol for HIV-associated NAFLD and lipodystrophy (ARRIVE) trial was a double-blind, randomized, investigator-initiated, placebo-controlled trial to test the efficacy of 12 weeks of treatment with aramchol versus placebo in HIV-associated NAFLD. "

08/01/2010 - "The aim of the present study was to investigate whether inhibition of SCD by Aramchol, a fatty acid bile conjugate with known hypocholesterolemic effects, will affect atherogenesis and how. "
08/01/2010 - "In ApoE(-/-), LDRL(-/-) and C57Bl6 mice, the effects of Aramchol on atherogenesis were non-atherogenic. "